BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Decraecker M, Toulouse C, Blanc JF. Is There Still a Place for Tyrosine Kinase Inhibitors for the Treatment of Hepatocellular Carcinoma at the Time of Immunotherapies? A Focus on Lenvatinib. Cancers (Basel) 2021;13:6310. [PMID: 34944930 DOI: 10.3390/cancers13246310] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Chen P, Li Y, Wei P, Liang L, Li B, Cao Y, Han X, Wang Y, Duan X, Jia H, Zhao T, Ren J. siRNA targeting PD-L1 delivered with attenuated Salmonella enhanced the anti-tumor effect of lenvatinib on mice bearing Hepatocellular carcinoma. Int Immunopharmacol 2022;111:109127. [PMID: 35964407 DOI: 10.1016/j.intimp.2022.109127] [Reference Citation Analysis]
2 Jiang W, Zhao T, Zhen X, Jin C, Li H, Ha J. Rapid Determination of 9 Tyrosine Kinase Inhibitors for the Treatment of Hepatocellular Carcinoma in Human Plasma by QuEChERS-UPLC-MS/MS. Front Pharmacol 2022;13:920436. [DOI: 10.3389/fphar.2022.920436] [Reference Citation Analysis]